Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[31] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
Fowler, Nathan H.
Davis, R. Eric
Rawal, Seema
Nastoupil, Loretta
Hagemeister, Fredrick B.
McLaughlin, Peter
Kwak, Larry W.
Romaguera, Jorge E.
Fanale, Michelle A.
Fayad, Luis E.
Westin, Jason R.
Shah, Jatin
Orlowski, Robert Z.
Wang, Michael
Turturro, Francesco
Oki, Yasuhiro
Claret, Linda C.
Feng, Lei
Baladandayuthapani, Veerabhadran
Muzzafar, Tariq
Tsai, Kenneth Y.
Samaniego, Felipe
Neelapu, Sattva S.
LANCET ONCOLOGY, 2014, 15 (12): : 1311 - 1318
[32] Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Lansigan, Frederick
Costa, Cristiana A.
Zaki, Bassem I.
Yen, Stephanie P.
Winer, Eric S.
Ryan, Helen
Findley, Darcie
Metzler, Sara R.
Shaw, Lynn
Toaso, Bonnie
MacKenzie, Todd A.
Chen, Youdinghuan
Beaven, Anne W.
CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6073 - 6079
[33] A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)
Christofyllakis, Konstantinos
Poeschel, Viola
Altmann, Bettina
Maurer, Stephanie
Lesan, Vadim
Bittenbring, Joerg
Kos, Igor Age
Kaddu-Mulindwa, Dominic
Abdi, Zanir
Fleser, Octavian
Altmeyer, Sarah
Neuendorff, Nina Rosa
Nickelsen, Maike
Held, Gerhard
Dreyling, Martin
Zettl, Florian
Buske, Christian
Lenz, Georg
Glass, Bertram
Chapuy, Bjoern
Schmitz, Norbert
Vassilakopoulos, Theodoros
Ott, German
Siebert, Reiner
Viardot, Andreas
Scherer, Florian
Schmitz, Roland
Rosenwald, Andreas
Hellwig, Dirk
Loeffler, Markus
Stilgenbauer, Stephan
Thurner, Lorenz
Bewarder, Moritz
Ziepert, Marita
BLOOD, 2023, 142
[34] Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently
Ambery, Claire
Young, Graeme
Fuller, Teresa
Georgiou, Alex
Ramsay, David
Puri, Adeep
Daley-Yates, Peter
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 188 - 197
[35] An open-label trial of rituximab in the treatment of patients with dermatomyositis
Chung, L
Fiorentino, D
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB77 - AB77
[36] Rituximab treatment in Myasthenia gravis: an open-label trial
Di Virgilio, G.
Zekeridou, A.
Menetrey, A.
Kuntzer, T.
JOURNAL OF NEUROLOGY, 2011, 258 : 248 - 248
[37] Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
Smith, V.
Van Praet, J. T.
Vandooren, B.
Van der Cruyssen, B.
Naeyaert, J-M
Decuman, S.
Elewaut, D.
De Keyser, F.
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 193 - 197
[38] Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study
Rigby, William F. C.
Mease, Philip J.
Olech, Ewa
Ashby, Mark
Tole, Swati
JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) : 599 - 604
[39] Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study
Fowler, Nathan
Nastoupil, Loretta
de Vos, Sven
Knapp, Mark
Flinn, Ian W.
Chen, Robert W.
Advani, Ranjana H.
Bhatia, Sumeet
Martin, Peter
Mena, Raul
Suzuki, Samuel
Beaupre, Darrin M.
Neuenburg, Jutta K.
Palomba, M. Lia
BLOOD, 2016, 128 (22)
[40] Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma
Sepmeyer, Jacob A.
Greer, John P.
Koyama, Tatsuki
Zic, John A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) : 584 - 587

← 1 2 3 4 5 →